ConductScience.org, home

Paper39201739

Serum TLR2 and TLR9 in Prostate Cancer Patients in Relation to EBV Status.

Sikora D and 4 others. Int J Mol Sci, 2024. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Serum TLR2 and TLR9 in Prostate Cancer Patients in Relation to EBV Status. Papers, record 39201739. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39201739

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Serum TLR2 and TLR9 in Prostate Cancer Patients in Relation to EBV Status.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.46, provisional
iCite
Revised in PubMed
2024-09-03
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sikora DDominikahttps://orcid.org/0000-0003-4031-7697
2Kiś JJacek
3Stępień EEwa
4Drop BBartłomiej
5Polz-Dacewicz MMałgorzatahttps://orcid.org/0000-0002-3222-184X

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Prostatic NeoplasmsMajor topic
Toll-Like Receptor 2Major topic
Toll-Like Receptor 9Major topic
Epstein-Barr Virus InfectionsMajor topic
Herpesvirus 4, HumanMajor topic
Humans
Male
Aged
Middle Aged
Neoplasm Grading

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
DS 233Medical University of LublinPubMed

Source PubMed

Download CSV of grants

References45

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120980631EBV latent membrane protein 1 is a negative regulator of TLR9.J Immunol2010https://conductscience.org/library/papers/20980631PubMed
233228078Epstein-Barr Virus: How Its Lytic Phase Contributes to Oncogenesis.Microorganisms2020https://conductscience.org/library/papers/33228078PubMed
335729214Detection and characterization of latency stage of EBV and histopathological analysis of prostatic adenocarcinoma tissues.Sci Rep2022https://conductscience.org/library/papers/35729214PubMed
437760627Epstein-Barr Virus Infection in Cancer.Cancers (Basel)2023https://conductscience.org/library/papers/37760627PubMed
522851253Human papillomavirus and Epstein Barr virus in prostate cancer: Koilocytes indicate potential oncogenic influences of human papillomavirus in prostate cancer.Prostate2013https://conductscience.org/library/papers/22851253PubMed
629496646Viral etiology of prostate cancer: Genetic alterations and immune response. A literature review.Int J Surg2018https://conductscience.org/library/papers/29496646PubMed
727052804Differential expression of EBV proteins LMP1 and BHFR1 in EBV‑associated gastric and nasopharyngeal cancer tissues.Mol Med Rep2016https://conductscience.org/library/papers/27052804PubMed
834749760Anti-viral and pro-inflammatory functions of Toll-like receptors during gamma-herpesvirus infections.Virol J2021https://conductscience.org/library/papers/34749760PubMed
925101092Toll-like receptors and prostate cancer.Front Immunol2014https://conductscience.org/library/papers/25101092PubMed
1038254816Can the Epstein-Barr Virus Play a Role in the Development of Prostate Cancer?Cancers (Basel)2024https://conductscience.org/library/papers/38254816PubMed
1122291478Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates.Clin Epidemiol2012https://conductscience.org/library/papers/22291478PubMed
1237637768Epstein-Barr Viral Infection and the Risk for Breast Cancer: A Systematic Review.Int J Hematol Oncol Stem Cell Res2023https://conductscience.org/library/papers/37637768PubMed
1332584450Prostate cancer cells modulate the differentiation of THP-1 cells in response to etoposide and TLR agonists treatments.Cell Biol Int2020https://conductscience.org/library/papers/32584450PubMed
1426046794TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.Oncotarget2015https://conductscience.org/library/papers/26046794PubMed
1533488588Epstein-Barr Virus and Systemic Autoimmune Diseases.Front Immunol2020https://conductscience.org/library/papers/33488588PubMed
1631341086Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection.Proc Natl Acad Sci U S A2019https://conductscience.org/library/papers/31341086PubMed
1737065193The innate and T-cell mediated immune response during acute and chronic gammaherpesvirus infection.Front Cell Infect Microbiol2023https://conductscience.org/library/papers/37065193PubMed
1831068988Epidemiology of Prostate Cancer.World J Oncol2019https://conductscience.org/library/papers/31068988PubMed
1938572751Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024https://conductscience.org/library/papers/38572751PubMed
2022311043Association of Toll-like receptor (TLR) 2, 3 and 9 genes polymorphism with prostate cancer risk in North Indian population.Mol Biol Rep2012https://conductscience.org/library/papers/22311043PubMed

See all 45 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
41601666Current update on toll-like receptors and prostate cancer: a decade of progress and emerging insights.Front Immunol2025https://conductscience.org/library/papers/41601666PubMed
40727252Toll-Like Receptors in the Immunotherapy Era: Dual-Edged Swords of Tumor Immunity and Clinical Translation.MedComm (2020)2025https://conductscience.org/library/papers/40727252PubMed
40151299Significant up-regulation of Toll-like receptor (TLR) signaling pathway in Epstein-Barr virus-associated gastric cancer.Int J Mol Epidemiol Genet2025https://conductscience.org/library/papers/40151299PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
TLR27097PubTator's text mininghttps://conductscience.org/library/genes/7097NCBI Gene
TLR954106PubTator's text mininghttps://conductscience.org/library/genes/54106NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39201739

GET https://conductscience.org/api/papers/v1/39201739/references?page=2